243 related articles for article (PubMed ID: 34642768)
21. A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia.
Mashor M; Wong KW; Tey KE; Choon SE
Med J Malaysia; 2022 Nov; 77(6):689-695. PubMed ID: 36448386
[TBL] [Abstract][Full Text] [Related]
22. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
[TBL] [Abstract][Full Text] [Related]
23. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
24. Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks.
Giometto S; Tillati S; Baglietto L; De Bortoli N; Mosca M; Conte M; Tuccori M; Gini R; Lucenteforte E
Int J Environ Res Public Health; 2022 Jun; 19(11):. PubMed ID: 35682382
[TBL] [Abstract][Full Text] [Related]
25. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
[TBL] [Abstract][Full Text] [Related]
28. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
30. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
31. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
32. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
33. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Singh S; Kalb RE; de Jong EMGJ; Shear NH; Lebwohl M; Langholff W; Hopkins L; Srivastava B; Armstrong AW
Am J Clin Dermatol; 2018 Dec; 19(6):879-886. PubMed ID: 30267377
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
35. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
36. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
[TBL] [Abstract][Full Text] [Related]
37. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
38. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
39. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
40. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
